High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma

Finn, 2020, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056/NEJMoa1915745 Cheng, 2022, Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma, J Hepatol, 76, 862, 10.1016/j.jhep.2021.11.030 Lee, 2020, Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity, Exp Mol Med, 52, 1475, 10.1038/s12276-020-00500-y Cheon, 2022, Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma, Liver Int, 42, 674, 10.1111/liv.15102 Maesaka, 2022, Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy, Hepatol Res, 52, 298, 10.1111/hepr.13741 Yumita, 2022, Analysis of hyperprogressive disease due to atezolizumab combined with bevacizumab treatment in patients with advanced hepatocellular carcinoma, Res Square Kim, 2022, Association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma, JAMA Oncol, 8, 10.1001/jamaoncol.2022.4733 An, 2021, Peripheral blood-based biomarkers for immune checkpoint inhibitors, Int J Mol Sci, 22, 9414, 10.3390/ijms22179414 Bruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199 Di Tommaso, 2019, Role of liver biopsy in hepatocellular carcinoma, World J Gastroenterol, 25, 6041, 10.3748/wjg.v25.i40.6041 Stenken, 2015, Bioanalytical chemistry of cytokines – a review, Anal Chim Acta, 853, 95, 10.1016/j.aca.2014.10.009 Hirano, 2000, Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors, Oncogene, 19, 2548, 10.1038/sj.onc.1203551 Kumari, 2016, Role of interleukin-6 in cancer progression and therapeutic resistance, Tumor Biol, 37, 11553, 10.1007/s13277-016-5098-7 Fisher, 2014, The two faces of IL-6 in the tumor microenvironment, Semin Immunol, 26, 38, 10.1016/j.smim.2014.01.008 Hoejberg, 2012, Interleukin-6 and melanoma, Melanoma Res, 22, 327, 10.1097/CMR.0b013e3283543d72 Ma, 2017, IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients, Adv Clin Exp Med, 26, 421, 10.17219/acem/62120 Feng, 2018, Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer, J Int Med Res, 46, 5228 Shakiba, 2018, Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis, Clin Exp Hepatol, 4, 182, 10.5114/ceh.2018.78122 Kalbasi, 2020, Tumour-intrinsic resistance to immune checkpoint blockade, Nat Rev Immunol, 20, 25, 10.1038/s41577-019-0218-4 Flint, 2016, Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity, Cell Metab, 24, 672, 10.1016/j.cmet.2016.10.010 Hailemichael, 2022, Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity, Cancer Cell, 40, 509, 10.1016/j.ccell.2022.04.004 Sang, 2022, High serum levels of IL-6 predict poor responses in patients treated with pembrolizumab plus axitinib for advanced renal cell carcinoma, Cancers (Basel), 14, 5985, 10.3390/cancers14235985 Tsukamoto, 2015, IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age, Nat Commun, 6, 1, 10.1038/ncomms7702 Nakanishi, 2009, CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help, Nature, 462, 510, 10.1038/nature08511 Tsukamoto, 2018, Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity, Cancer Sci, 109, 523, 10.1111/cas.13433 Heimbach, 2018, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 67, 358, 10.1002/hep.29086 Jiang, 2018, Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response, Nat Med, 24, 1550, 10.1038/s41591-018-0136-1 Park, 2021, High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer, J Immunother Cancer, 9 Yang, 2019, STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade, J Clin Invest, 129, 4350, 10.1172/JCI125413 Lausen, 1992, Maximally selected rank statistics, Biometrics, 48, 73, 10.2307/2532740 Scheiner, 2022, Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score, J Hepatol, 76, 353, 10.1016/j.jhep.2021.09.035 Yavuz, 2021, Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma, J Hepatocell Carcinoma, 8, 1195, 10.2147/JHC.S322289 Hyung, 2022, Histopathologic and molecular biomarkers of PD-1/PD-L1 inhibitor treatment response among patients with microsatellite instability-high colon cancer, Cancer Res Treat, 54, 1175, 10.4143/crt.2021.1133 Kim, 2021, Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer, Cancers (Basel), 13, 4906, 10.3390/cancers13194906 Villaruz, 2013, The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement, Clin Cancer Res, 19, 2629, 10.1158/1078-0432.CCR-12-2935 Myojin, 2022, Interleukin-6 is a circulating prognostic biomarker for hepatocellular carcinoma patients Treated with Combined Immunotherapy, Cancers, 14, 883, 10.3390/cancers14040883 Kitamura, 2017, Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy, Cancer Sci, 108, 1947, 10.1111/cas.13332 Weber, 2021, IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy, Cell Immunol, 359, 10.1016/j.cellimm.2020.104254 Hardy-Werbin, 2019, Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer, Oncoimmunology, 8, 10.1080/2162402X.2019.1593810 Laino, 2020, Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition, J Immunother Cancer, 8